Aspirin for primary prevention of cardiovascular disease in diabetes mellitus - Wikidata - awgldk - TriplyDB

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

http://www.wikidata.org/entity/Q35132896

about

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events Community pharmacists' interest in and attitude to pharmacy practice research in Ethiopia: A cross-sectional study.Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke.Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions.Aspirin for primary prevention of cardiovascular disease events.Updates in antiplatelet agents used in cardiovascular diseases.Anthocyanins in obesity-associated thrombogenesis: a review of the potential mechanism of action.Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes.Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.Becatamide Found in Houttuynia cordata Suppresses P-selectin Expression Via Inhibiting COX Enzyme, Not Increasing cAMP in Platelets.Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease

P2860

Q26995752-7E4DFB35-9E7E-4676-9524-FEE21A26FF0E Q33803191-5AE0B496-E243-44DF-B3A6-FE5C979F4980 Q33949522-51D21FAC-3814-4C3B-87A9-853F41AEC310 Q35022756-8A759865-A9B1-4119-A5DA-FD1D4E16A6A9 Q35043219-F1B1CD25-3EA9-43FD-8ED5-7C0B156A0C96 Q35174193-32D3F7DF-EBDC-4178-91B6-764E6C55AFBF Q37145480-43F0061C-ADA7-42CC-95E6-B594AE7EB75F Q37992812-6AC6BF93-0FDE-417A-94DD-4C2709A6B2AC Q37998509-3FD2FA56-1321-47AD-B674-65DEC71D65B1 Q38047265-E37A5A0C-7D44-4066-AECE-9F0244D2CB59 Q38161394-D26AFDF4-1B5F-4E56-ABC6-89EC675AB7DB Q38797634-70AE5C7A-AE20-474B-B782-1243F84F59B8 Q39366558-125DA3D1-6454-4FCD-8433-280819A9C078 Q43563736-ADC837D9-0348-4478-A895-8C120AF76A68 Q53210327-EEE2221C-F494-450B-ADBC-637A8008C86F Q57789721-8FB5F336-E2E1-40DB-A11F-AA7E24CBF382

P2860

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

http://www.wikidata.org/entity/Q35132896

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@ast

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@en

type

label

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@ast

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@en

prefLabel

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@ast

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@en

P1433

Q35132896-0AFB33A4-E166-4BAB-A4F4-2D6EB4CE6B00

P1476

Q35132896-AEEEE80A-6365-458A-8080-D3BDD4E4DE42

P2093

Q35132896-8DD61E3C-B9E7-4C1C-88F1-801847314918

P2860

Q35132896-02291DDD-F749-4E8E-88B0-32DF84EB7CE8

Q35132896-02D6775C-6773-45E7-93D3-03B7240D53A5

Q35132896-038FC110-6DDC-4254-A76B-BE2303A45B1E

Q35132896-0471D025-7585-4D04-8336-8E7108A7620E

Q35132896-0A5EA1FF-7585-4122-97EF-4B99FA103F74

Q35132896-0ABE8BC4-5987-4CD2-8A81-8FD333F39EA8

Q35132896-0D102923-7DD8-4F95-BAA4-4CF5B9827FE0

Q35132896-112B2F2A-94DA-4665-A006-D92B51DE0CD2

Q35132896-13DF5155-BAD3-413E-83BE-DBF32D12C30E

Q35132896-1586D3BE-F66C-487D-A77F-BB8B4E86237C

P2888

Q35132896-E00290CA-0D7A-4484-9929-358912895CBB

P304

Q35132896-5950B1A9-C014-4480-9D9C-D167B342AF85

P31

Q35132896-C26E92C4-E0BD-4A34-9EC5-185B74185248

P356

Q35132896-7CF959CF-CD38-41B0-A501-60632D8A9AA1

P433

Q35132896-1B7642CD-5BFF-48D9-A2D5-E1187C76DCDA

P478

Q35132896-E6A7ED53-23E7-493A-AE9C-35431FC0A472

P50

Q35132896-A9FA6634-96F2-4F85-94EB-47F3839E2704

P577

Q35132896-5A5A7798-B0AF-4629-B064-E76E061124C0

P5875

Q35132896-30CF5BC5-4B8D-4137-835F-4DF88D1CA13A

P6179

Q35132896-4BFEB7FD-FF3A-4089-888E-93B14A7A23A1

P698

Q35132896-95E30302-1FC3-431B-BE18-6491A5D72D4E

P921

Q35132896-19BBBE23-00ED-4962-8A0D-844EEF5C181B

P932

Q35132896-B4B8A265-5748-4F45-8B4E-C73BEB61BBF7

P356

NRENDO.2010.169

P1433

Nature Reviews Endocrinology

P1476

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus

@en

P2093

Craig D Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

An editorial update: should she take aspirin?

P2888

nrendo.2010.169

P304

619-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2010.169

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Pignone

P577

2010-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46381779

http://www.w3.org/2001/XMLSchema#string

P6179

1025903856

http://www.w3.org/2001/XMLSchema#string

P698

20856266

http://www.w3.org/2001/XMLSchema#string

P921

P932

3145323

http://www.w3.org/2001/XMLSchema#string